

Zhe-Sheng Chen

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6362085/zhe-sheng-chen-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

369
papers

14,921
citations

59
h-index

109
g-index

405
ext. papers

17,742
ext. citations

8.1
avg. IF

6.78
L-index

#	Paper	IF	Citations
369	The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials. <i>Chemical Society Reviews</i> , 2017 , 46, 5771-5804	58.5	573
368	Silver nanoparticles: synthesis, properties, and therapeutic applications. <i>Drug Discovery Today</i> , 2015 , 20, 595-601	8.8	541
367	The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade. <i>Drug Resistance Updates</i> , 2015 , 18, 1-17	23.2	463
366	Biosynthesis of Nanoparticles by Microorganisms and Their Applications. <i>Journal of Nanomaterials</i> , 2011 , 2011, 1-16	3.2	396
365	Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies. <i>Drug Resistance Updates</i> , 2016 , 27, 14-29	23.2	362
364	Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. <i>Cancer Research</i> , 2008 , 68, 7905-14	10.1	321
363	Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. <i>Journal of Biological Chemistry</i> , 2001 , 276, 33747-54 [†]	5.4	308
362	Autophagy and multidrug resistance in cancer. <i>Chinese Journal of Cancer</i> , 2017 , 36, 52		295
361	Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. <i>Cancer Research</i> , 2010 , 70, 7981-91	10.1	255
360	Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. <i>Cancer Research</i> , 2007 , 67, 11012-20	10.1	252
359	Modulating ROS to overcome multidrug resistance in cancer. <i>Drug Resistance Updates</i> , 2018 , 41, 1-25	23.2	238
358	Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. <i>Cancer Research</i> , 2002 , 62, 3144-50	10.1	224
357	Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. <i>Cancer Research</i> , 2003 , 63, 4048-54	10.1	218
356	BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. <i>Leukemia Research</i> , 2010 , 34, 1255-68	2.7	208
355	Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases. <i>FEBS Journal</i> , 2011 , 278, 3226-45	5.7	193
354	MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2',3'-dideoxycytidine and 9'-(2'-phosphonylmethoxyethyl)adenine. <i>Journal of Biological Chemistry</i> , 2003 , 278, 29509-14	5.4	190
353	Nilotinib (AMN107, Tassigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. <i>Biochemical Pharmacology</i> , 2009 , 78, 153-61	6	179

352	Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel. <i>Cancer Research</i> , 2004 , 64, 4927-30	10.1	177
351	Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). <i>Cancer Research</i> , 2002 , 62, 6172-7	10.1	175
350	Multidrug resistance associated proteins in multidrug resistance. <i>Chinese Journal of Cancer</i> , 2012 , 31, 58-72		165
349	Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells. <i>Journal of the National Cancer Institute</i> , 1999 , 91, 1647-53	9.7	164
348	Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. <i>Molecular Pharmacology</i> , 1999 , 56, 1219-28	4.3	158
347	Revisiting the ABCs of multidrug resistance in cancer chemotherapy. <i>Current Pharmaceutical Biotechnology</i> , 2011 , 12, 570-94	2.6	155
346	Analysis of the in vivo functions of Mrp3. <i>Molecular Pharmacology</i> , 2005 , 68, 160-8	4.3	155
345	Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). <i>Molecular Pharmacology</i> , 2003 , 63, 351-8	4.3	149
344	Paclitaxel Through the Ages of Anticancer Therapy: Exploring Its Role in Chemoresistance and Radiation Therapy. <i>Cancers</i> , 2015 , 7, 2360-71	6.6	143
343	Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. <i>Cancer Research</i> , 2011 , 71, 3029-41	10.1	139
342	Transport of bile acids, sulfated steroids, estradiol 17-beta-D-glucuronide, and leukotriene C4 by human multidrug resistance protein 8 (ABCC11). <i>Molecular Pharmacology</i> , 2005 , 67, 545-57	4.3	137
341	MRP subfamily transporters and resistance to anticancer agents. <i>Journal of Bioenergetics and Biomembranes</i> , 2001 , 33, 493-501	3.7	129
340	Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance. <i>Drug Resistance Updates</i> , 2012 , 15, 70-80	23.2	128
339	Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo. <i>Cancer Biology and Therapy</i> , 2006 , 5, 39-47	4.6	127
338	Enhanced transport of anticancer agents and leukotriene C4 by the human canalicular multispecific organic anion transporter (cMOAT/MRP2). <i>FEBS Letters</i> , 1999 , 456, 327-31	3.8	127
337	Multidrug Resistance Proteins (MRPs) and Cancer Therapy. <i>AAPS Journal</i> , 2015 , 17, 802-12	3.7	123
336	Elevated expression of vacuolar proton pump genes and cellular PH in cisplatin resistance. <i>International Journal of Cancer</i> , 2001 , 93, 869-74	7.5	112
335	Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B. <i>Cancer Research</i> , 2009 , 69, 178-84	10.1	105

334	circKIF4A acts as a prognostic factor and mediator to regulate the progression of triple-negative breast cancer. <i>Molecular Cancer</i> , 2019 , 18, 23	42.1	100
333	ABCC10, ABCC11, and ABCC12. <i>Pflugers Archiv European Journal of Physiology</i> , 2007 , 453, 675-84	4.6	100
332	Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. <i>Cancer Letters</i> , 2009 , 279, 74-83	9.9	99
331	Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update. <i>Drug Resistance Updates</i> , 2020 , 49, 100681	23.2	93
330	Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models. <i>Cancer Letters</i> , 2013 , 328, 307-17	9.9	92
329	Cytokines in cancer drug resistance: Cues to new therapeutic strategies. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2016 , 1865, 255-65	11.2	91
328	Tyrosine kinase inhibitors as reversal agents for ABC transporter mediated drug resistance. <i>Molecules</i> , 2014 , 19, 13848-77	4.8	83
327	Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance. <i>Drug Resistance Updates</i> , 2020 , 48, 100663	23.2	80
326	Neratinib reverses ATP-binding cassette B1-mediated chemotherapeutic drug resistance in vitro, in vivo, and ex vivo. <i>Molecular Pharmacology</i> , 2012 , 82, 47-58	4.3	79
325	A Novel Potent Anticancer Compound Optimized from a Natural Oridonin Scaffold Induces Apoptosis and Cell Cycle Arrest through the Mitochondrial Pathway. <i>Journal of Medicinal Chemistry</i> , 2017 , 60, 1449-1468	8.3	75
324	Enhanced chemosensitization in multidrug-resistant human breast cancer cells by inhibition of IL-6 and IL-8 production. <i>Breast Cancer Research and Treatment</i> , 2012 , 135, 737-47	4.4	73
323	Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance. <i>Biochemical Pharmacology</i> , 2010 , 79, 154-61	6	71
322	The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms. <i>Biochemical Pharmacology</i> , 2013 , 85, 514-24	6	69
321	The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2. <i>Molecular Cancer Therapeutics</i> , 2012 , 11, 2033-44	6.1	69
320	RNA interference targeting the CD147 induces apoptosis of multi-drug resistant cancer cells related to XIAP depletion. <i>Cancer Letters</i> , 2009 , 276, 189-95	9.9	68
319	Expression of ABCC-type nucleotide exporters in blasts of adult acute myeloid leukemia: relation to long-term survival. <i>Clinical Cancer Research</i> , 2009 , 15, 1762-9	12.9	67
318	Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters. <i>Cancer Letters</i> , 2018 , 421, 186-198	9.9	66
317	miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 3137-51	6.1	63

316	Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. <i>Biochemical Pharmacology</i> , 2009 , 77, 781-93	6	63
315	Long non-coding RNAs regulate drug resistance in cancer. <i>Molecular Cancer</i> , 2020 , 19, 54	42.1	62
314	The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporter. <i>PLoS ONE</i> , 2011 , 6, e19329	3.7	62
313	Oncosis-inducing cyclometalated iridium(III) complexes. <i>Chemical Science</i> , 2018 , 9, 5183-5190	9.4	60
312	Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10). <i>PLoS ONE</i> , 2009 , 4, e7520	3.7	59
311	Agosterol A, a novel polyhydroxylated sterol acetate reversing multidrug resistance from a marine sponge of <i>Spongia</i> sp.. <i>Tetrahedron Letters</i> , 1998 , 39, 6303-6306	2	58
310	Cepharanthine is a potent reversal agent for MRP7(ABCC10)-mediated multidrug resistance. <i>Biochemical Pharmacology</i> , 2009 , 77, 993-1001	6	57
309	Reversal of drug resistance mediated by multidrug resistance protein (MRP) 1 by dual effects of agosterol A on MRP1 function. <i>International Journal of Cancer</i> , 2001 , 93, 107-113	7.5	57
308	Current status on marine products with reversal effect on cancer multidrug resistance. <i>Marine Drugs</i> , 2012 , 10, 2312-21	6	56
307	GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse ABCG2- and ABCB1-mediated drug resistance. <i>Biochemical Pharmacology</i> , 2012 , 83, 1613-22	6	55
306	Glutathione-dependent binding of a photoaffinity analog of agosterol A to the C-terminal half of human multidrug resistance protein. <i>Journal of Biological Chemistry</i> , 2001 , 276, 23197-206	5.4	55
305	TCPs: privileged scaffolds for identifying potent LSD1 inhibitors for cancer therapy. <i>Epigenomics</i> , 2016 , 8, 651-66	4.4	55
304	Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells. <i>Cancer Letters</i> , 2019 , 440-441, 82-93	9.9	55
303	Contribution of Abcc10 (Mrp7) to in vivo paclitaxel resistance as assessed in Abcc10(-/-) mice. <i>Cancer Research</i> , 2011 , 71, 3649-57	10.1	54
302	Reversing effect of agosterol A, a spongean sterol acetate, on multidrug resistance in human carcinoma cells. <i>Japanese Journal of Cancer Research</i> , 2001 , 92, 886-95		54
301	Chemical molecular-based approach to overcome multidrug resistance in cancer by targeting P-glycoprotein (P-gp). <i>Medicinal Research Reviews</i> , 2021 , 41, 525-555	14.4	54
300	Discovery of Novel Quinoline-Chalcone Derivatives as Potent Antitumor Agents with Microtubule Polymerization Inhibitory Activity. <i>Journal of Medicinal Chemistry</i> , 2019 , 62, 993-1013	8.3	53
299	Roles of sildenafil in enhancing drug sensitivity in cancer. <i>Cancer Research</i> , 2011 , 71, 3735-8	10.1	52

298	Reversal of P-glycoprotein-mediated multidrug resistance by sipholane triterpenoids. <i>Journal of Natural Products</i> , 2007 , 70, 928-31	4.9	52
297	Sipholenol A, a marine-derived sipholane triterpene, potently reverses P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells. <i>Cancer Science</i> , 2007 , 98, 1373-80	6.9	51
296	Targeted deletion of both thymidine phosphorylase and uridine phosphorylase and consequent disorders in mice. <i>Molecular and Cellular Biology</i> , 2002 , 22, 5212-21	4.8	51
295	Lamellarin O, a pyrrole alkaloid from an Australian marine sponge, <i>Ianthella</i> sp., reverses BCRP mediated drug resistance in cancer cells. <i>Marine Drugs</i> , 2014 , 12, 3818-37	6	50
294	Marine sponge-derived sipholane triterpenoids reverse P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells. <i>Biochemical Pharmacology</i> , 2010 , 80, 1497-506	6	49
293	Up-regulation of MRP4 and down-regulation of influx transporters in human leukemic cells with acquired resistance to 6-mercaptopurine. <i>Leukemia Research</i> , 2008 , 32, 799-809	2.7	49
292	Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells. <i>Chinese Journal of Cancer</i> , 2012 , 31, 110-8		49
291	Probing the Anticancer Action of Oridonin with Fluorescent Analogues: Visualizing Subcellular Localization to Mitochondria. <i>Journal of Medicinal Chemistry</i> , 2016 , 59, 5022-34	8.3	49
290	Triterpenoids as reversal agents for anticancer drug resistance treatment. <i>Drug Discovery Today</i> , 2014 , 19, 482-8	8.8	48
289	Multidrug resistance proteins (MRPs): Structure, function and the overcoming of cancer multidrug resistance. <i>Drug Resistance Updates</i> , 2021 , 54, 100743	23.2	48
288	Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1. <i>Biochemical Pharmacology</i> , 2014 , 90, 367-78	6	46
287	Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance. <i>Cancers</i> , 2014 , 6, 1925-52	6.6	46
286	An active efflux system for heavy metals in cisplatin-resistant human KB carcinoma cells. <i>Experimental Cell Research</i> , 1998 , 240, 312-20	4.2	46
285	Autophagy and transporter-based multi-drug resistance. <i>Cells</i> , 2012 , 1, 558-75	7.9	44
284	Sipholane triterpenoids: chemistry, reversal of ABCB1/P-glycoprotein-mediated multidrug resistance, and pharmacophore modeling. <i>Journal of Natural Products</i> , 2009 , 72, 1291-8	4.9	44
283	Reversal of heavy metal resistance in multidrug-resistant human KB carcinoma cells. <i>Biochemical and Biophysical Research Communications</i> , 1997 , 236, 586-90	3.4	44
282	Novel hybrids of natural oridonin-bearing nitrogen mustards as potential anticancer drug candidates. <i>ACS Medicinal Chemistry Letters</i> , 2014 , 5, 797-802	4.3	43
281	Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo. <i>Biochemical Pharmacology</i> , 2014 , 89, 52-61	6	43

280	Bafetinib (INNO-406) reverses multidrug resistance by inhibiting the efflux function of ABCB1 and ABCG2 transporters. <i>Scientific Reports</i> , 2016 , 6, 25694	4.9	42
279	In vitro, in vivo and ex vivo characterization of ibrutinib: a potent inhibitor of the efflux function of the transporter MRP1. <i>British Journal of Pharmacology</i> , 2014 , 171, 5845-57	8.6	42
278	PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 72, 189-99	3.5	42
277	The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance. <i>Oncology Reports</i> , 2009 , 21, 483-9	3.5	42
276	The PI3K subunits, P110 α and P110 β are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer. <i>Molecular Cancer</i> , 2020 , 19, 10	42.1	41
275	Elemene, a compound derived from <i>Rhizoma zedoariae</i> , reverses multidrug resistance mediated by the ABCB1 transporter. <i>Oncology Reports</i> , 2014 , 31, 858-66	3.5	41
274	Overexpression of Survivin and XIAP in MDR cancer cells unrelated to P-glycoprotein. <i>Oncology Reports</i> , 2007 , 17, 969-76	3.5	41
273	Regorafenib overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter in colorectal cancer: In vitro and in vivo study. <i>Cancer Letters</i> , 2017 , 396, 145-154	9.9	39
272	Design and synthesis of human ABCB1 (P-glycoprotein) inhibitors by peptide coupling of diverse chemical scaffolds on carboxyl and amino termini of (S)-valine-derived thiazole amino acid. <i>Journal of Medicinal Chemistry</i> , 2014 , 57, 4058-72	8.3	39
271	Blockade of Her2/neu binding to Hsp90 by emodin azide methyl anthraquinone derivative induces proteasomal degradation of Her2/neu. <i>Molecular Pharmaceutics</i> , 2011 , 8, 1687-97	5.6	39
270	BBA, a derivative of 23-hydroxybetulinic acid, potently reverses ABCB1-mediated drug resistance in vitro and in vivo. <i>Molecular Pharmaceutics</i> , 2012 , 9, 3147-59	5.6	38
269	Reversal of multidrug resistance in human carcinoma cell line by agosterols, marine spongean sterols. <i>Tetrahedron</i> , 1999 , 55, 13965-13972	2.4	38
268	Surmounting cancer drug resistance: New insights from the perspective of N-methyladenosine RNA modification. <i>Drug Resistance Updates</i> , 2020 , 53, 100720	23.2	38
267	Discovery of 5-Cyano-6-phenylpyrimidin Derivatives Containing an Acylurea Moiety as Orally Bioavailable Reversal Agents against P-Glycoprotein-Mediated Mutidrug Resistance. <i>Journal of Medicinal Chemistry</i> , 2018 , 61, 5988-6001	8.3	38
266	Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2. <i>Oncotarget</i> , 2014 , 5, 4529-42	3.3	37
265	VS-4718 Antagonizes Multidrug Resistance in ABCB1- and ABCG2-Overexpressing Cancer Cells by Inhibiting the Efflux Function of ABC Transporters. <i>Frontiers in Pharmacology</i> , 2018 , 9, 1236	5.6	36
264	Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. <i>Biochemical Pharmacology</i> , 2018 , 158, 274-285	6	36
263	Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells. <i>Biochemical Pharmacology</i> , 2019 , 166, 120-127	6	35

262	Recent advances regarding the role of ABC subfamily C member 10 (ABCC10) in the efflux of antitumor drugs. <i>Chinese Journal of Cancer</i> , 2014 , 33, 223-30		35
261	Saracatinib (AZD0530) is a potent modulator of ABCB1-mediated multidrug resistance in vitro and in vivo. <i>International Journal of Cancer</i> , 2013 , 132, 224-35	7.5	35
260	Masitinib antagonizes ATP-binding cassette subfamily C member 10-mediated paclitaxel resistance: a preclinical study. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 714-23	6.1	35
259	The combination of disulfiram and copper for cancer treatment. <i>Drug Discovery Today</i> , 2020 , 25, 1099-1108	10.8	34
258	Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells. <i>Cellular Physiology and Biochemistry</i> , 2018 , 45, 1515-1528	3.9	34
257	PDE5 inhibitors, sildenafil and vardenafil, reverse multidrug resistance by inhibiting the efflux function of multidrug resistance protein 7 (ATP-binding Cassette C10) transporter. <i>Cancer Science</i> , 2012 , 103, 1531-7	6.9	34
256	Semi-synthetic ocotillol analogues as selective ABCB1-mediated drug resistance reversal agents. <i>Oncotarget</i> , 2015 , 6, 24277-90	3.3	33
255	Enhancing chemosensitivity in ABCB1- and ABCG2-overexpressing cells and cancer stem-like cells by an Aurora kinase inhibitor CCT129202. <i>Molecular Pharmaceutics</i> , 2012 , 9, 1971-82	5.6	33
254	5-hydroxytryptamine receptor (5-HT1DR) promotes colorectal cancer metastasis by regulating Axin1/Ectenin/MMP-7 signaling pathway. <i>Oncotarget</i> , 2015 , 6, 25975-87	3.3	33
253	Olmudinib (BI1482694/HM61713), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses ABCG2-Mediated Multidrug Resistance in Cancer Cells. <i>Frontiers in Pharmacology</i> , 2018 , 9, 1097	5.6	32
252	Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: In vitro and in vivo. <i>Cancer Letters</i> , 2018 , 424, 19-29	9.9	31
251	Evodiamine Suppresses ABCG2 Mediated Drug Resistance by Inhibiting p50/p65 NF- κ B Pathway in Colorectal Cancer. <i>Journal of Cellular Biochemistry</i> , 2016 , 117, 1471-81	4.7	31
250	Tandutinib (MLN518) reverses multidrug resistance by inhibiting the efflux activity of the multidrug resistance protein 7 (ABCC10). <i>Oncology Reports</i> , 2013 , 29, 2479-85	3.5	31
249	Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19. <i>Pharmacology & Therapeutics</i> , 2020 , 216, 107672	13.9	31
248	Exploration of 1,2,3-triazole-pyrimidine hybrids as potent reversal agents against ABCB1-mediated multidrug resistance. <i>European Journal of Medicinal Chemistry</i> , 2018 , 143, 1535-1542	6.8	30
247	Reversal of MRP7 (ABCC10)-mediated multidrug resistance by tariquidar. <i>PLoS ONE</i> , 2013 , 8, e55576	3.7	30
246	Tetrandrine Interaction with ABCB1 Reverses Multidrug Resistance in Cancer Cells Through Competition with Anti-Cancer Drugs Followed by Downregulation of ABCB1 Expression. <i>Molecules</i> , 2019 , 24,	4.8	30
245	Venetoclax, a BCL-2 Inhibitor, Enhances the Efficacy of Chemotherapeutic Agents in Wild-Type ABCG2-Overexpression-Mediated MDR Cancer Cells. <i>Cancers</i> , 2020 , 12,	6.6	29

244	AST1306, a potent EGFR inhibitor, antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance. <i>Cancer Letters</i> , 2014 , 350, 61-8	9.9	29
243	Characterization of the ATP-dependent LTC ₄ transporter in cisplatin-resistant human KB cells. <i>Biochemical and Biophysical Research Communications</i> , 1996 , 226, 158-65	3.4	29
242	Synergistic antitumor activity of regorafenib and lapatinib in preclinical models of human colorectal cancer. <i>Cancer Letters</i> , 2017 , 386, 100-109	9.9	28
241	Cellular mechanisms of the cytotoxicity of the anticancer drug elesclomol and its complex with Cu(II). <i>Biochemical Pharmacology</i> , 2015 , 93, 266-76	6	28
240	Increased sensitivity to vincristine of MDR cells by the leukotriene D ₄ receptor antagonist, ONO-1078. <i>Cancer Letters</i> , 1998 , 130, 175-82	9.9	28
239	Osimertinib (AZD9291), a Mutant-Selective EGFR Inhibitor, Reverses ABCB1-Mediated Drug Resistance in Cancer Cells. <i>Molecules</i> , 2016 , 21,	4.8	28
238	Microbiota in health and diseases.. <i>Signal Transduction and Targeted Therapy</i> , 2022 , 7, 135	21	28
237	Ganoderma lucidum derived ganoderenic acid B reverses ABCB1-mediated multidrug resistance in HepG2/ADM cells. <i>International Journal of Oncology</i> , 2015 , 46, 2029-38	4.4	27
236	Reversal of MRP-mediated vincristine resistance in KB cells by buthionine sulfoximine in combination with PAK-104P. <i>Cancer Letters</i> , 1998 , 129, 69-76	9.9	27
235	Reversal of P-glycoprotein and multidrug-resistance protein-mediated drug resistance in KB cells by 5-O-benzoylated taxinine K. <i>Molecular Pharmacology</i> , 2000 , 58, 1563-9	4.3	27
234	Epitranscriptomics and epiproteomics in cancer drug resistance: therapeutic implications. <i>Signal Transduction and Targeted Therapy</i> , 2020 , 5, 193	21	27
233	Therapeutic strategies to overcome taxane resistance in cancer. <i>Drug Resistance Updates</i> , 2021 , 55, 1007542	5.4	27
232	Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance. <i>International Journal of Biochemistry and Cell Biology</i> , 2014 , 51, 111-9	5.6	26
231	Masitinib antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance. <i>International Journal of Oncology</i> , 2014 , 44, 1634-42	4.4	26
230	The small molecule tyrosine kinase inhibitor NVP-BHG712 antagonizes ABCC10-mediated paclitaxel resistance: a preclinical and pharmacokinetic study. <i>Oncotarget</i> , 2015 , 6, 510-21	3.3	26
229	The BTK Inhibitor Ibrutinib (PCI-32765) Overcomes Paclitaxel Resistance in ABCB1- and ABCC10-Overexpressing Cells and Tumors. <i>Molecular Cancer Therapeutics</i> , 2017 , 16, 1021-1030	6.1	25
228	The reversal of antineoplastic drug resistance in cancer cells by Elemenene. <i>Chinese Journal of Cancer</i> , 2015 , 34, 488-95		25
227	Parguerenes: Marine red alga bromoditerpenes as inhibitors of P-glycoprotein (ABCB1) in multidrug resistant human cancer cells. <i>Biochemical Pharmacology</i> , 2013 , 85, 1257-68	6	25

226	Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function. <i>Biochemical Pharmacology</i> , 2009 , 78, 355-64	6	25
225	Proteome analysis of multidrug resistance of human oral squamous carcinoma cells using CD147 silencing. <i>Journal of Proteome Research</i> , 2008 , 7, 4784-91	5.6	25
224	Gold nanoparticles: synthesis, physiochemical properties and therapeutic applications in cancer. <i>Drug Discovery Today</i> , 2021 , 26, 1284-1292	8.8	25
223	Gaseous signaling molecules and their application in resistant cancer treatment: from invisible to visible. <i>Future Medicinal Chemistry</i> , 2019 ,	4.1	24
222	Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance. <i>Cancers</i> , 2020 , 12,	6.6	24
221	The targeting of non-coding RNAs by curcumin: Facts and hopes for cancer therapy (Review). <i>Oncology Reports</i> , 2019 , 42, 20-34	3.5	24
220	Tivozanib reverses multidrug resistance mediated by ABCB1 (P-glycoprotein) and ABCG2 (BCRP). <i>Future Oncology</i> , 2014 , 10, 1827-41	3.6	24
219	Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update. <i>Frontiers in Immunology</i> , 2021 , 12, 658519	8.4	24
218	Exploring Phytochemicals for Combating Antibiotic Resistance in Microbial Pathogens. <i>Frontiers in Pharmacology</i> , 2021 , 12, 720726	5.6	24
217	Exploring naturally occurring ivy nanoparticles as an alternative biomaterial. <i>Acta Biomaterialia</i> , 2015 , 25, 268-83	10.8	23
216	Effect of Y6, an epigallocatechin gallate derivative, on reversing doxorubicin drug resistance in human hepatocellular carcinoma cells. <i>Oncotarget</i> , 2017 , 8, 29760-29770	3.3	23
215	6,7-Seco-ent-Kauranoids Derived from Oridonin as Potential Anticancer Agents. <i>Journal of Natural Products</i> , 2017 , 80, 2391-2398	4.9	23
214	Chloroquine against malaria, cancers and viral diseases. <i>Drug Discovery Today</i> , 2020 , 25, 2012-2012	8.8	23
213	Selective reversal of BCRP-mediated MDR by VEGFR-2 inhibitor ZM323881. <i>Biochemical Pharmacology</i> , 2017 , 132, 29-37	6	22
212	Midostaurin Reverses ABCB1-Mediated Multidrug Resistance, an Study. <i>Frontiers in Oncology</i> , 2019 , 9, 514	5.3	22
211	Ponatinib enhances anticancer drug sensitivity in MRP7-overexpressing cells. <i>Oncology Reports</i> , 2014 , 31, 1605-12	3.5	22
210	Tandutinib (MLN518/CT53518) targeted to stem-like cells by inhibiting the function of ATP-binding cassette subfamily G member 2. <i>European Journal of Pharmaceutical Sciences</i> , 2013 , 49, 441-50	5.1	22
209	Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and in vivo. <i>Cancer Letters</i> , 2019 , 442, 91-103	9.9	22

208	Regorafenib antagonizes BCRP-mediated multidrug resistance in colon cancer. <i>Cancer Letters</i> , 2019 , 442, 104-112	9.9	22
207	Zafirlukast antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance. <i>Anti-Cancer Drugs</i> , 2012 , 23, 865-73	2.4	21
206	Quizartinib (AC220) reverses ABCG2-mediated multidrug resistance: and studies. <i>Oncotarget</i> , 2017 , 8, 93785-93799	3.3	21
205	IKK inhibition increases bortezomib effectiveness in ovarian cancer. <i>Oncotarget</i> , 2015 , 6, 26347-58	3.3	21
204	Tea nanoparticle, a safe and biocompatible nanocarrier, greatly potentiates the anticancer activity of doxorubicin. <i>Oncotarget</i> , 2016 , 7, 5877-91	3.3	21
203	Benzoyl indoles with metabolic stability as reversal agents for ABCG2-mediated multidrug resistance. <i>European Journal of Medicinal Chemistry</i> , 2019 , 179, 849-862	6.8	20
202	Overexpression of ABCB1 Transporter Confers Resistance to mTOR Inhibitor WYE-354 in Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	20
201	WHI-P154 enhances the chemotherapeutic effect of anticancer agents in ABCG2-overexpressing cells. <i>Cancer Science</i> , 2014 , 105, 1071-8	6.9	20
200	OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistance. <i>Biochemical Pharmacology</i> , 2012 , 84, 766-74	6	20
199	PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia. <i>Cancer Letters</i> , 2016 , 383, 220-229	9.9	20
198	Novel nanomedicines to overcome cancer multidrug resistance. <i>Drug Resistance Updates</i> , 2021 , 58, 100773.2	7.2	20
197	CDX2 Stimulates the Proliferation of Porcine Intestinal Epithelial Cells by Activating the mTORC1 and Wnt/ECatenin Signaling Pathways. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	19
196	Functional comparison between YCF1 and MRP1 expressed in Sf21 insect cells. <i>Biochemical and Biophysical Research Communications</i> , 2000 , 270, 608-15	3.4	19
195	Derivative of 5-cyano-6-phenylpyrimidin antagonizes ABCB1- and ABCG2-mediated multidrug resistance. <i>European Journal of Pharmacology</i> , 2019 , 863, 172611	5.3	18
194	From Antimicrobial to Anticancer Peptides: The Transformation of Peptides. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2019 , 14, 70-84	2.6	18
193	Sitravatinib, a Tyrosine Kinase Inhibitor, Inhibits the Transport Function of ABCG2 and Restores Sensitivity to Chemotherapy-Resistant Cancer Cells. <i>Frontiers in Oncology</i> , 2020 , 10, 700	5.3	18
192	Fragmented polymer nanotubes from sonication-induced scission with a thermo-responsive gating system for anti-cancer drug delivery. <i>Journal of Materials Chemistry B</i> , 2014 , 2, 1327-1334	7.3	18
191	PD173074, a selective FGFR inhibitor, reverses MRP7 (ABCC10)-mediated MDR. <i>Acta Pharmaceutica Sinica B</i> , 2014 , 4, 202-7	15.5	18

190	Dual TTK/CLK2 inhibitor, CC-671, selectively antagonizes ABCG2-mediated multidrug resistance in lung cancer cells. <i>Cancer Science</i> , 2020 , 111, 2872-2882	6.9	18
189	BIRB796, the inhibitor of p38 mitogen-activated protein kinase, enhances the efficacy of chemotherapeutic agents in ABCB1 overexpression cells. <i>PLoS ONE</i> , 2013 , 8, e54181	3.7	18
188	Modulating the function of ATP-binding cassette subfamily G member 2 (ABCG2) with inhibitor cabozantinib. <i>Pharmacological Research</i> , 2017 , 119, 89-98	10.2	17
187	GSK1904529A, a Potent IGF-IR Inhibitor, Reverses MRP1-Mediated Multidrug Resistance. <i>Journal of Cellular Biochemistry</i> , 2017 , 118, 3260-3267	4.7	17
186	Glesatinib, a c-MET/SMO Dual Inhibitor, Antagonizes P-glycoprotein Mediated Multidrug Resistance in Cancer Cells. <i>Frontiers in Oncology</i> , 2019 , 9, 313	5.3	17
185	Revisiting the role of nanoparticles as modulators of drug resistance and metabolism in cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016 , 12, 281-9	5.5	17
184	Chk1 Inhibitor MK-8776 Restores the Sensitivity of Chemotherapeutics in P-glycoprotein Overexpressing Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	16
183	ATP-binding cassette subfamily B member 1 (ABCB1) and subfamily C member 10 (ABCC10) are not primary resistance factors for cabazitaxel. <i>Chinese Journal of Cancer</i> , 2015 , 34, 115-20		16
182	ARRY-334543 reverses multidrug resistance by antagonizing the activity of ATP-binding cassette subfamily G member 2. <i>Journal of Cellular Biochemistry</i> , 2014 , 115, 1381-91	4.7	16
181	Ciprofloxacin Enhances the Chemosensitivity of Cancer Cells to ABCB1 Substrates. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	16
180	Discovery of Potent Inhibitors against P-Glycoprotein-Mediated Multidrug Resistance Aided by Late-Stage Functionalization of a 2-(4-(Pyridin-2-yl)phenoxy)pyridine Analogue. <i>Journal of Medicinal Chemistry</i> , 2020 , 63, 5458-5476	8.3	15
179	Comprehensive Synthesis of Amino Acid-Derived Thiazole Peptidomimetic Analogues to Understand the Enigmatic Drug/Substrate-Binding Site of P-Glycoprotein. <i>Journal of Medicinal Chemistry</i> , 2018 , 61, 834-864	8.3	15
178	CEP-33779 antagonizes ATP-binding cassette subfamily B member 1 mediated multidrug resistance by inhibiting its transport function. <i>Biochemical Pharmacology</i> , 2014 , 91, 144-56	6	15
177	Esters of the marine-derived triterpene siphonolol A reverse P-GP-mediated drug resistance. <i>Marine Drugs</i> , 2015 , 13, 2267-86	6	15
176	A-803467, a tetrodotoxin-resistant sodium channel blocker, modulates ABCG2-mediated MDR in vitro and in vivo. <i>Oncotarget</i> , 2015 , 6, 39276-91	3.3	15
175	Acerinol, a cyclolanthane triterpenoid from <i>Cimicifuga acerina</i> , reverses ABCB1-mediated multidrug resistance in HepG2/ADM and MCF-7/ADR cells. <i>European Journal of Pharmacology</i> , 2014 , 733, 34-44	5.3	15
174	Design, synthesis and biological evaluation of N-arylphenyl-2,2-dichloroacetamide analogues as anti-cancer agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012 , 22, 7268-71	2.9	15
173	Multidrug resistance reversal activity of taxoids from <i>Taxus cuspidata</i> in KB-C2 and 2780AD cells. <i>Japanese Journal of Cancer Research</i> , 2000 , 91, 638-42		15

172	Identification of a distinct luminal subgroup diagnosing and stratifying early stage prostate cancer by tissue-based single-cell RNA sequencing. <i>Molecular Cancer</i> , 2020 , 19, 147	42.1	15
171	Modulating the function of ABCB1: in vitro and in vivo characterization of sitravatinib, a tyrosine kinase inhibitor. <i>Cancer Communications</i> , 2020 , 40, 285-300	9.4	14
170	Fexofenadine inhibits TNF signaling through targeting to cytosolic phospholipase A2 and is therapeutic against inflammatory arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1524-1535	2.4	14
169	An enhanced active efflux of CPT-11 and SN-38 in cisplatin-resistant human KB carcinoma cells. <i>Cancer Letters</i> , 1999 , 138, 13-22	9.9	14
168	Antimicrobial Peptide Reverses ABCB1-Mediated Chemotherapeutic Drug Resistance. <i>Frontiers in Pharmacology</i> , 2020 , 11, 1208	5.6	14
167	Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function. <i>Drug Resistance Updates</i> , 2021 , 57, 100770	23.2	14
166	M3814, a DNA-PK Inhibitor, Modulates ABCG2-Mediated Multidrug Resistance in Lung Cancer Cells. <i>Frontiers in Oncology</i> , 2020 , 10, 674	5.3	13
165	Biological evaluation of non-basic chalcone CYB-2 as a dual ABCG2/ABCB1 inhibitor. <i>Biochemical Pharmacology</i> , 2020 , 175, 113848	6	13
164	Design, synthesis and biological evaluation of benzamide and phenyltetrazole derivatives with amide and urea linkers as BCRP inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017 , 27, 4698-4704	2.9	13
163	B4G2 induces mitochondrial apoptosis by the ROS-mediated opening of Ca(2+)-dependent permeability transition pores. <i>Cellular Physiology and Biochemistry</i> , 2015 , 37, 838-52	3.9	13
162	Repurposing phosphodiesterase-5 inhibitors as chemoadjuvants. <i>Frontiers in Pharmacology</i> , 2013 , 4, 82	5.6	13
161	Lapatinib promotes the incidence of hepatotoxicity by increasing chemotherapeutic agent accumulation in hepatocytes. <i>Oncotarget</i> , 2015 , 6, 17738-52	3.3	13
160	Genetic biomarkers of drug resistance: A compass of prognosis and targeted therapy in acute myeloid leukemia. <i>Drug Resistance Updates</i> , 2020 , 52, 100703	23.2	13
159	Establishment and characterization of arsenic trioxide resistant KB/ATO cells. <i>Acta Pharmaceutica Sinica B</i> , 2017 , 7, 564-570	15.5	12
158	Suppression of ABCG2 mediated MDR in vitro and in vivo by a novel inhibitor of ABCG2 drug transport. <i>Pharmacological Research</i> , 2017 , 121, 184-193	10.2	12
157	Anti-cancer effect of Indanone-based thiazolyl hydrazone derivative on colon cancer cell lines. <i>International Journal of Biochemistry and Cell Biology</i> , 2019 , 110, 21-28	5.6	12
156	Colchicine Binding Site Agent DJ95 Overcomes Drug Resistance and Exhibits Antitumor Efficacy. <i>Molecular Pharmacology</i> , 2019 , 96, 73-89	4.3	12
155	Structure-Based Design, Synthesis, and Biological Evaluation of New Triazolo[1,5-]Pyrimidine Derivatives as Highly Potent and Orally Active ABCB1 Modulators. <i>Journal of Medicinal Chemistry</i> , 2020 , 63, 15979-15996	8.3	12

154	Characterization of a novel HDAC/RXR/HtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancer. <i>Molecular Cancer</i> , 2020 , 19, 134	42.1	12
153	Bruton's Tyrosine Kinase (BTK) Inhibitor RN486 Overcomes ABCB1-Mediated Multidrug Resistance in Cancer Cells. <i>Frontiers in Cell and Developmental Biology</i> , 2020 , 8, 865	5.7	12
152	Expression of ABCB6 is related to resistance to 5-FU, SN-38 and vincristine. <i>Anticancer Research</i> , 2014 , 34, 4767-73	2.3	12
151	Revisiting mTOR inhibitors as anticancer agents. <i>Drug Discovery Today</i> , 2019 , 24, 2086-2095	8.8	11
150	Identification of a Potent Oridonin Analogue for Treatment of Triple-Negative Breast Cancer. <i>Journal of Medicinal Chemistry</i> , 2020 , 63, 8157-8178	8.3	11
149	Overexpression of ABCG2 confers resistance to pevonedistat, an NAE inhibitor. <i>Experimental Cell Research</i> , 2020 , 388, 111858	4.2	11
148	Uncaria alkaloids reverse ABCB1-mediated cancer multidrug resistance. <i>International Journal of Oncology</i> , 2017 , 51, 257-268	4.4	11
147	bba, a synthetic derivative of 23-hydroxybutulinic acid, reverses multidrug resistance by inhibiting the efflux activity of MRP7 (ABCC10). <i>PLoS ONE</i> , 2013 , 8, e74573	3.7	11
146	A multi-functionalized nanocomposite constructed by gold nanorod core with triple-layer coating to combat multidrug resistant colorectal cancer. <i>Materials Science and Engineering C</i> , 2020 , 107, 110224	8.3	11
145	The epigallocatechin gallate derivative Y reverses drug resistance mediated by the ABCB1 transporter both and. <i>Acta Pharmaceutica Sinica B</i> , 2019 , 9, 316-323	15.5	11
144	Patterned Synthesis of ZnO Nanorod Arrays for Nanoplasmonic Waveguide Applications. <i>Optics Communications</i> , 2018 , 411, 53-58	2	11
143	A personalized and long-acting local therapeutic platform combining photothermal therapy and chemotherapy for the treatment of multidrug-resistant colon tumor. <i>International Journal of Nanomedicine</i> , 2018 , 13, 8411-8427	7.3	11
142	Design, synthesis and biological evaluation of WZ4002 analogues as EGFR inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017 , 27, 4832-4837	2.9	10
141	Reversal Effect of ALK Inhibitor NVP-TAE684 on ABCG2-Overexpressing Cancer Cells. <i>Frontiers in Oncology</i> , 2020 , 10, 228	5.3	10
140	Synthesis and biological evaluation of indole-based UC-112 analogs as potent and selective survivin inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2018 , 149, 211-224	6.8	10
139	Discovery of a non-toxic [1,2,4]triazolo[1,5-a]pyrimidin-7-one (WS-10) that modulates ABCB1-mediated multidrug resistance (MDR). <i>Bioorganic and Medicinal Chemistry</i> , 2018 , 26, 5006-5017	3.4	10
138	Reversal of Cancer Multidrug Resistance (MDR) Mediated by ATP-Binding Cassette Transporter G2 (ABCG2) by AZ-628, a RAF Kinase Inhibitor. <i>Frontiers in Cell and Developmental Biology</i> , 2020 , 8, 601400	5.7	10
137	ABCG2 Overexpression Contributes to Pevonedistat Resistance. <i>Cancers</i> , 2020 , 12,	6.6	9

136	Epigenetic regulation of ferroptosis via ETS1/miR-23a-3p/ACSL4 axis mediates sorafenib resistance in human hepatocellular carcinoma.. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022 , 41, 3	12.8	9
135	Hsa_circ_0003258 promotes prostate cancer metastasis by complexing with IGF2BP3 and sponging miR-653-5p.. <i>Molecular Cancer</i> , 2022 , 21, 12	42.1	9
134	Sulindac sulfide selectively increases sensitivity of ABCC1 expressing tumor cells to doxorubicin and glutathione depletion. <i>Journal of Biomedical Research</i> , 2016 , 30, 120-133	1.5	9
133	The emerging nature of Ubiquitin-specific protease 7 (USP7): a new target in cancer therapy. <i>Drug Discovery Today</i> , 2021 , 26, 490-502	8.8	9
132	Sapitinib Reverses Anticancer Drug Resistance in Colon Cancer Cells Overexpressing the ABCB1 Transporter. <i>Frontiers in Oncology</i> , 2020 , 10, 574861	5.3	8
131	New phenstatin-fatty acid conjugates: synthesis and evaluation. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013 , 23, 5119-22	2.9	8
130	Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia. <i>Cancer Letters</i> , 2020 , 472, 132-141	9.9	8
129	Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction. <i>Protein and Cell</i> , 2021 , 12, 586-591	7.2	8
128	Mechanisms of thrombosis and research progress on targeted antithrombotic drugs. <i>Drug Discovery Today</i> , 2021 , 26, 2282-2302	8.8	8
127	Elevated ABCB1 Expression Confers Acquired Resistance to Aurora Kinase Inhibitor GSK-1070916 in Cancer Cells. <i>Frontiers in Pharmacology</i> , 2020 , 11, 615824	5.6	8
126	Long noncoding RNAs have pivotal roles in chemoresistance of acute myeloid leukemia. <i>Drug Discovery Today</i> , 2021 , 26, 1735-1743	8.8	8
125	Enhanced nucleotide excision repair in cisplatin resistant human KB carcinoma cells. <i>Oncology Reports</i> , 2002 , 9, 839-44	3.5	8
124	Thiazole-valine peptidomimetic (TTT-28) antagonizes multidrug resistance in vitro and in vivo by selectively inhibiting the efflux activity of ABCB1. <i>Scientific Reports</i> , 2017 , 7, 42106	4.9	7
123	Y, an Epigallocatechin Gallate Derivative, Reverses ABCG2-Mediated Mitoxantrone Resistance. <i>Frontiers in Pharmacology</i> , 2018 , 9, 1545	5.6	7
122	1,2,3-Triazole-Dithiocarbamate Hybrids, a Group of Novel Cell Active SIRT1 Inhibitors. <i>Cellular Physiology and Biochemistry</i> , 2016 , 38, 185-93	3.9	7
121	TC > 0.05 as a Pharmacokinetic Parameter of Paclitaxel for Therapeutic Efficacy and Toxicity in Cancer Patients. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2018 , 13, 341-347	2.6	7
120	Enzyme and Transporter Kinetics for CPT-11 (Irinotecan) and SN-38: An Insight on Tumor Tissue Compartment Pharmacokinetics Using PBPK. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2019 , 14, 177-186	2.6	7
119	BMS-599626, a Highly Selective Pan-HER Kinase Inhibitor, Antagonizes ABCG2-Mediated Drug Resistance. <i>Cancers</i> , 2020 , 12,	6.6	7

118	The role of endolysosomal trafficking in anticancer drug resistance. <i>Drug Resistance Updates</i> , 2021 , 57, 100769	23.2	7
117	Isolation and characterization of arsenite-resistant human epidermoid carcinoma KB cells. <i>Oncology Reports</i> , 2007 , 18, 721-7	3.5	7
116	An organoruthenium complex overcomes ABCG2-mediated multidrug resistance via multiple mechanisms. <i>Chemical Communications</i> , 2019 , 55, 3833-3836	5.8	6
115	Bipiperidinyl derivatives of 23-hydroxybetulinic acid reverse resistance of HepG2/ADM and MCF-7/ADR cells. <i>Anti-Cancer Drugs</i> , 2013 , 24, 441-54	2.4	6
114	Inhibition of c-Kit, VEGFR-2 (KDR), and ABCG2 by analogues of OSI-930. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011 , 21, 6495-9	2.9	6
113	Overexpression of human ATP-binding cassette transporter ABCG2 contributes to reducing the cytotoxicity of GSK1070916 in cancer cells. <i>Biomedicine and Pharmacotherapy</i> , 2021 , 136, 111223	7.5	6
112	OTS964, a TOPK Inhibitor, Is Susceptible to ABCG2-Mediated Drug Resistance. <i>Frontiers in Pharmacology</i> , 2021 , 12, 620874	5.6	6
111	ATP-binding cassette (ABC) transporters in cancer: A review of recent updates. <i>Journal of Evidence-Based Medicine</i> , 2021 , 14, 232-256	6.1	6
110	Discovery of New 4-Indolyl Quinazoline Derivatives as Highly Potent and Orally Bioavailable P-Glycoprotein Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2021 , 64, 14895-14911	8.3	6
109	m6A modification: recent advances, anticancer targeted drug discovery and beyond.. <i>Molecular Cancer</i> , 2022 , 21, 52	42.1	6
108	N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer.. <i>Nature Communications</i> , 2022 , 13, 2672	17.4	6
107	2-Trifluoromethyl-2-Hydroxypropionamide Derivatives as Novel Reversal Agents of ABCG2 (BCRP)-Mediated Multidrug Resistance: Synthesis and Biological Evaluations. <i>Journal of Cellular Biochemistry</i> , 2017 , 118, 2420-2429	4.7	5
106	Establishment and Characterization of a Topotecan Resistant Non-small Cell Lung Cancer NCI-H460/TPT10 Cell Line. <i>Frontiers in Cell and Developmental Biology</i> , 2020 , 8, 607275	5.7	5
105	Recent progress in antitumor functions of the intracellular antibodies. <i>Drug Discovery Today</i> , 2020 , 25, 1109-1120	8.8	5
104	Plasminogen activator inhibitor (PAI) trap3, an exocellular peptide inhibitor of PAI-1, attenuates the rearrangement of F-actin and migration of cancer cells. <i>Experimental Cell Research</i> , 2020 , 391, 111987	4.2	5
103	Discovery of the Triazolo[1,5-]Pyrimidine-Based Derivative WS-898 as a Highly Efficacious and Orally Bioavailable ABCB1 Inhibitor Capable of Overcoming Multidrug Resistance. <i>Journal of Medicinal Chemistry</i> , 2021 , 64, 16187-16204	8.3	5
102	Cytokine detection by flow cytometry. <i>Methods in Molecular Biology</i> , 2014 , 1172, 235-42	1.4	5
101	NVP-CGM097, an HDM2 Inhibitor, Antagonizes ATP-Binding Cassette Subfamily B Member 1-Mediated Drug Resistance. <i>Frontiers in Oncology</i> , 2020 , 10, 1219	5.3	5

100	Combination of Cordycepin and Apatinib Synergistically Inhibits NSCLC Cells by Down-Regulating VEGF/PI3K/Akt Signaling Pathway. <i>Frontiers in Oncology</i> , 2020 , 10, 1732	5.3	5
99	Natural Product as Substrates of ABC Transporters: A Review. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2021 , 16, 222-238	2.6	5
98	The role of androgen therapy in prostate cancer: from testosterone replacement therapy to bipolar androgen therapy. <i>Drug Discovery Today</i> , 2021 , 26, 1293-1301	8.8	5
97	Features of Cytokine Storm Identified by Distinguishing Clinical Manifestations in COVID-19. <i>Frontiers in Public Health</i> , 2021 , 9, 671788	6	5
96	Development of Alectinib-Based PROTACs as Novel Potent Degraders of Anaplastic Lymphoma Kinase (ALK). <i>Journal of Medicinal Chemistry</i> , 2021 , 64, 9120-9140	8.3	5
95	Overexpression of ABCC1 Confers Drug Resistance to Betulin. <i>Frontiers in Oncology</i> , 2021 , 11, 640656	5.3	5
94	Formulation and characterization of oleic acid magnetic PEG PLGA nanoparticles for targeting glioblastoma multiforme. <i>Journal of Magnetism and Magnetic Materials</i> , 2021 , 533, 167970	2.8	5
93	Phytochemical Delivery Through Transferosome (Phytosome): An Advanced Transdermal Drug Delivery for Complementary Medicines.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 850862	5.6	5
92	Proteomics technologies for cancer liquid biopsies.. <i>Molecular Cancer</i> , 2022 , 21, 53	42.1	5
91	2-Deoxy-D-Glucose and its Derivatives for the COVID-19 Treatment: An Update.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 899633	5.6	5
90	Synthesis and Cytotoxicity Studies of Stilbene Long-Chain Fatty Acid Conjugates. <i>Journal of Natural Products</i> , 2020 , 83, 1563-1570	4.9	4
89	Synthesis and evaluation of sulfonylethyl-containing phosphotriesters of 3'-azido-3'-deoxythymidine as anticancer prodrugs. <i>Bioorganic and Medicinal Chemistry</i> , 2014 , 22, 5747-5844	5.4	4
88	Up-regulation of P-glycoprotein confers acquired resistance to 6-mercaptopurine in human chronic myeloid leukemia cells. <i>Oncology Letters</i> , 2011 , 2, 549-556	2.6	4
87	Overexpression of Survivin and XIAP in MDR cancer cells unrelated to P-glycoprotein. <i>Oncology Reports</i> , 2007 ,	3.5	4
86	A Small Molecule Inhibitor, OGP46, Is Effective against Imatinib-Resistant BCR-ABL Mutations via the BCR-ABL/JAK-STAT Pathway. <i>Molecular Therapy - Oncolytics</i> , 2020 , 18, 137-148	6.4	4
85	Discovery of novel N-benzylbenzamide derivatives as tubulin polymerization inhibitors with potent antitumor activities. <i>European Journal of Medicinal Chemistry</i> , 2021 , 216, 113316	6.8	4
84	Establishment and Characterization of an Irinotecan-Resistant Human Colon Cancer Cell Line. <i>Frontiers in Oncology</i> , 2020 , 10, 624954	5.3	4
83	The Novel Benzamide Derivative, VKNG-2, Restores the Efficacy of Chemotherapeutic Drugs in Colon Cancer Cell Lines by Inhibiting the ABCG2 Transporter. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	4

82	Overcoming multidrug resistance by knockout of ABCB1 gene using CRISPR/Cas9 system in SW620/Ad300 colorectal cancer cells.. <i>MedComm</i> , 2021 , 2, 765-777	2.2	4
81	Quercetin ameliorates oxidative stress-induced cell apoptosis of seminal vesicles via activating Nrf2 in type 1 diabetic rats. <i>Biomedicine and Pharmacotherapy</i> , 2022 , 151, 113108	7.5	4
80	EGFR and HER2 Inhibitors as Sensitizing Agents for Cancer Chemotherapy 2019 , 1-11		3
79	Methyl-Cantharidimide (MCA) Has Anticancer Efficacy in ABCB1- and ABCG2-Overexpressing and Cisplatin Resistant Cancer Cells. <i>Frontiers in Oncology</i> , 2020 , 10, 932	5.3	3
78	Lipid-Saporin Nanoparticles for the Intracellular Delivery of Cytotoxic Protein to Overcome ABC Transporter-Mediated Multidrug Resistance In Vitro and In Vivo. <i>Cancers</i> , 2020 , 12,	6.6	3
77	Susceptibility of Lung Carcinoma Cells to Nanostructured Lipid Carrier of ARV-825, a BRD4 Degrading Proteolysis Targeting Chimera.. <i>Pharmaceutical Research</i> , 2022 , 1	4.5	3
76	Discovery of Novel Polycyclic Heterocyclic Derivatives from Evodiamine for the Potential Treatment of Triple-Negative Breast Cancer. <i>Journal of Medicinal Chemistry</i> , 2021 , 64, 17346-17365	8.3	3
75	Exploration of Antibiotic Activity of Aminoglycosides, in Particular Ribostamycin Alone and in Combination With Ethylenediaminetetraacetic Acid Against Pathogenic Bacteria. <i>Frontiers in Microbiology</i> , 2020 , 11, 1718	5.7	3
74	OGP46 Induces Differentiation of Acute Myeloid Leukemia Cells via Different Optimal Signaling Pathways. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 652972	5.7	3
73	Bypassing P-glycoprotein mediated efflux of afatinib by cyclodextrin complexation [Evaluation of intestinal absorption and anti-cancer activity. <i>Journal of Molecular Liquids</i> , 2021 , 327, 114866	6	3
72	Target Inhibition of CBP Induced Cell Senescence in BCR-ABL- T315I Mutant Chronic Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2020 , 10, 588641	5.3	3
71	Insights on the structure-function relationship of human multidrug resistance protein 7 (MRP7/ABCC10) from molecular dynamics simulations and docking studies. <i>MedComm</i> , 2021 , 2, 221-235 ^{2.2}	2.2	3
70	Antineoplastic activity of <i>Holoptelea integrifolia</i> (Roxb.) Planch bark extracts (in vitro). <i>Pakistan Journal of Pharmaceutical Sciences</i> , 2013 , 26, 1151-6	0.4	3
69	Fiber-Optic Theranostics (FOT): Interstitial Fiber-Optic Needles for Cancer Sensing and Therapy.. <i>Advanced Science</i> , 2022 , e2200456	13.6	3
68	CDK6-PI3K signaling axis is an efficient target for attenuating ABCB1/P-gp mediated multi-drug resistance (MDR) in cancer cells.. <i>Molecular Cancer</i> , 2022 , 21, 103	42.1	3
67	ABC Transporter Modulatory Drugs from Marine Sources: A New Approach to Overcome Drug Resistance in Cancer. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2015 , 183-208	0.3	2
66	Reversal effect of BM-cyclin 1 on multidrug resistance in C-A120 cells. <i>Anti-Cancer Drugs</i> , 2007 , 18, 1015-24		2
65	Identification of new potent anticancer derivatives through simplifying the core structure and modification on their 14- hydroxyl group from oridonin.. <i>European Journal of Medicinal Chemistry</i> , 2022 , 231, 114155	6.8	2

64	Targeting HNRNPU to overcome cisplatin resistance in bladder cancer.. <i>Molecular Cancer</i> , 2022 , 21, 37	42.1	2
63	Abstract 2983: A synthetic derivative of 1,2,3-triazole-pyrimidine hybrid reverses multidrug resistance mediated by MRP7 2020 ,		2
62	Recent Updates in Experimental Research and Clinical Evaluation on Drugs for COVID-19 Treatment. <i>Frontiers in Pharmacology</i> , 2021 , 12, 732403	5.6	2
61	Selpercatinib for lung and thyroid cancers with RET gene mutations or fusions. <i>Drugs of Today</i> , 2021 , 57, 621-629	2.5	2
60	Ginsenoside Rg3 Promotes Cell Growth Through Activation of mTORC1. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 730309	5.7	2
59	Natural Products: A Promising Therapeutics for Targeting Tumor Angiogenesis. <i>Frontiers in Oncology</i> , 2021 , 11, 772915	5.3	2
58	RNA methylation and cancer treatment. <i>Pharmacological Research</i> , 2021 , 174, 105937	10.2	2
57	Receptors and ligands for herpes simplex viruses: Novel insights for drug targeting. <i>Drug Discovery Today</i> , 2021 , 27, 185-185	8.8	2
56	Multifaceted anti-colorectal tumor effect of digoxin on HCT8 and SW620 cells. <i>Gastroenterology Report</i> , 2020 , 8, 465-475	3.3	2
55	The Discovery of Novel BCR-ABL Tyrosine Kinase Inhibitors Using a Pharmacophore Modeling and Virtual Screening Approach. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 649434	5.7	2
54	Cabozantinib Reverses Topotecan Resistance in Human Non-Small Cell Lung Cancer NCI-H460/TPT10 Cell Line and Tumor Xenograft Model. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 640957	5.7	2
53	AZ32 Reverses ABCG2-Mediated Multidrug Resistance in Colorectal Cancer. <i>Frontiers in Oncology</i> , 2021 , 11, 680663	5.3	2
52	Enhancement of anticancer drug sensitivity in multidrug resistance cells overexpressing ATP-binding cassette (ABC) transporter ABCC10 by CP55, a synthetic derivative of 5-cyano-6-phenylpyrimidin. <i>Experimental Cell Research</i> , 2021 , 405, 112728	4.2	2
51	CMP25, a synthetic new agent, targets multidrug resistance-associated protein 7 (MRP7/ABCC10). <i>Biochemical Pharmacology</i> , 2021 , 190, 114652	6	2
50	Drug resistance: from bacteria to cancer.. <i>Molecular Biomedicine</i> , 2021 , 2, 27	3.1	2
49	The Spleen Tyrosine Kinase Inhibitor, Entospletinib (GS-9973) Restores Chemosensitivity in Lung Cancer Cells by Modulating ABCG2-mediated Multidrug Resistance. <i>International Journal of Biological Sciences</i> , 2021 , 17, 2652-2665	11.2	2
48	Nano-Drug Delivery Systems Entrapping Natural Bioactive Compounds for Cancer: Recent Progress and Future Challenges.. <i>Frontiers in Oncology</i> , 2022 , 12, 867655	5.3	2
47	Hsa-miR-3178/RhoB/PI3K/Akt, a novel signaling pathway regulates ABC transporters to reverse gemcitabine resistance in pancreatic cancer.. <i>Molecular Cancer</i> , 2022 , 21, 112	42.1	2

46	Detailed resume of RNA m6A demethylases. <i>Acta Pharmaceutica Sinica B</i> , 2022 ,	15.5	1
45	Digoxin targets low density lipoprotein receptor-related protein 4 and protects against osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	1
44	Podophyllum hexandrum and its active constituents: Novel radioprotectants.. <i>Biomedicine and Pharmacotherapy</i> , 2021 , 146, 112555	7.5	1
43	Anticancer Activity of Oldenlandia Diffusa & Viola Philippica Car. <i>Journal of Cancer Research Updates</i> ,	1	1
42	Sildenafil Enhances the Anticancer Activity of Paclitaxel in an ABCB1-Mediated Multidrug Resistance Xenograft Mouse Model. <i>Journal of Cancer Research Updates</i> , 2014 , 3, 169-173	1	1
41	Bufalin Induces Apoptosis of MDA-MB-231 Cell Through Activation of JNK/p53 Pathway. <i>Journal of Cancer Research Updates</i> , 2015 , 4, 47-53	1	1
40	Cycloruthenated Self-Assembly with Metabolic Inhibition to Efficiently Overcome Multidrug Resistance in Cancers. <i>Advanced Materials</i> , 2021 , 34, e2100245	24	1
39	Extracellular Vesicles in Acute Leukemia: A Mesmerizing Journey With a Focus on Transferred microRNAs. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 766371	5.7	1
38	Design, synthesis and biological evaluation of selective survivin inhibitors. <i>Journal of Biomedical Research</i> , 2019 , 33, 82-100	1.5	1
37	Paclitaxel and chemoresistance 2022 , 251-267		1
36	A Circulating Exosome RNA Signature Is a Potential Diagnostic Marker for Pancreatic Cancer, a Systematic Study. <i>Cancers</i> , 2021 , 13,	6.6	1
35	Tepotinib hydrochloride for the treatment of non-small cell lung cancer. <i>Drugs of Today</i> , 2021 , 57, 265-275;		1
34	MG53 suppresses tumor progression and stress granule formation by modulating G3BP2 activity in non-small cell lung cancer. <i>Molecular Cancer</i> , 2021 , 20, 118	42.1	1
33	Establishment and Characterization of a Novel Multidrug Resistant Human Ovarian Cancer Cell Line With Heterogenous MRP7 Overexpression. <i>Frontiers in Oncology</i> , 2021 , 11, 731260	5.3	1
32	Overexpression of ABCB1 Associated With the Resistance to the KRAS-G12C Specific Inhibitor ARS-1620 in Cancer Cells.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 843829	5.6	1
31	Tisotumab vedotin for the treatment of cervical carcinoma.. <i>Drugs of Today</i> , 2022 , 58, 213-222	2.5	1
30	PBK/TOPK inhibitor OTS964 resistance is mediated by ABCB1-dependent transport function in cancer: in vitro and in vivo study.. <i>Molecular Cancer</i> , 2022 , 21, 40	42.1	0
29	Methyltransferase like 7B is a potential therapeutic target for reversing EGFR-TKIs resistance in lung adenocarcinoma.. <i>Molecular Cancer</i> , 2022 , 21, 43	42.1	0

28	Hydroxychloroquine synergizes with the PI3K inhibitor BKM120 to exhibit antitumor efficacy independent of autophagy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021 , 40, 374	12.8	o
27	Anticancer Activity of Five Traditionally Used Medicinal Plants Extracts. <i>Journal of Cancer Research Updates</i> , 2014 , 3, 103-107	1	o
26	Overexpression of ABCG2 Confers Resistance to MLN7243, a Ubiquitin-Activating Enzyme (UAE) Inhibitor. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 697927	5.7	o
25	Lurbinectedin for the treatment of small cell lung cancer. <i>Drugs of Today</i> , 2021 , 57, 377-385	2.5	o
24	Recent progress on targeting leukemia stem cells. <i>Drug Discovery Today</i> , 2021 , 26, 1904-1913	8.8	o
23	Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.. <i>Drugs of Today</i> , 2022 , 58, 175-185	2.5	o
22	Idecabtagene vicleucel for relapsed/refractory multiple myeloma: a review of recent advances.. <i>Drugs of Today</i> , 2022 , 58, 117-132	2.5	o
21	Abiraterone, Orteronel, Enzalutamide and Docetaxel: Sequential or Combined Therapy?. <i>Frontiers in Pharmacology</i> , 2022 , 13, 843110	5.6	o
20	The Resistance of Cancer Cells to Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, is Mediated by the ABCB1 Transporter.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 861642	5.6	o
19	The Discovery of Novel PGK1 Activators as Apoptotic Inhibiting and Neuroprotective Agents.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 877706	5.6	o
18	Redox signaling-governed drug-tolerant persister cancer cell: a key spark of treatment failure.. <i>Signal Transduction and Targeted Therapy</i> , 2022 , 7, 89	21	o
17	The Potential Role of Exosomes in the Treatment of Brain Tumors, Recent Updates and Advances.. <i>Frontiers in Oncology</i> , 2022 , 12, 869929	5.3	o
16	Ribociclib Inhibits P-gp-Mediated Multidrug Resistance in Human Epidermoid Carcinoma Cells.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 867128	5.6	o
15	The Histone Deacetylase Inhibitor I13 Induces Differentiation of M2, M3 and M5 Subtypes of Acute Myeloid Leukemia Cells and Leukemic Stem-Like Cells.. <i>Frontiers in Oncology</i> , 2022 , 12, 855570	5.3	o
14	Therapeutic implication of carbon monoxide in drug resistant cancers.. <i>Biochemical Pharmacology</i> , 2022 , 201, 115061	6	o
13	BCR-ABL Inhibitors as Sensitizing Agents for Cancer Chemotherapy 2019 , 13-27		
12	P-gp Inhibitory Activity from Marine Sponges, Tunicates and Algae 2015 , 593-619		
11	Enhanced nucleotide excision repair in cisplatin resistant human KB carcinoma cells. <i>Oncology Reports</i> , 2002 , 9, 839	3.5	

10	Pharmacotherapeutic Options for Philadelphia Chromosome- Positive CML. <i>Journal of Cancer Research Updates</i> , 2018 , 7, 49-58	1
9	Paclitaxel and cancer treatment: Non-mitotic mechanisms of paclitaxel action in cancer therapy 2022 , 269-286	
8	Construction and Validation of a Nomogram for Predicting Progression- Free Survival in Patients with Early-Stage Testicular Germ Cell Tumor. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2021 , 16, 44-53	2.6
7	The Oncogenic Protein, Breakpoint Cluster (BCR)-Abelson Kinase (ABL) and Chronic Myelocytic Leukemia (CML): Insight Into the Drug Resistance Mechanisms and Approaches for Targeting BCR-ABL in CML 2021 ,	
6	Selection of optimal therapeutic modality for early-stage extranodal natural killer/T-cell lymphoma patients under the guidance of single-nucleotide polymorphism signature. <i>Bosnian Journal of Basic Medical Sciences</i> , 2021 ,	3.3
5	CUL4 Lung Adenocarcinomas Are Dependent on the CUL4-p21 Ubiquitin Signaling for Proliferation and Survival. <i>American Journal of Pathology</i> , 2021 , 191, 1638-1650	5.8
4	Research progress in overcoming ibrutinib drug resistance.. <i>Drugs of Today</i> , 2022 , 58, 85-94	2.5
3	Therapeutic Implication of Oxidative Stress Regulators in Drug-Resistant Cancers 2022 , 1-20	
2	Mechanism of N-Methyl-N-Nitroso-Urea-Induced Gastric Precancerous Lesions in Mice.. <i>Journal of Oncology</i> , 2022 , 2022, 3780854	4.5
1	An Ayurgenomics Approach: Prakriti-Based Drug Discovery and Development for Personalized Care.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 866827	5.6